Evidence map›Paper›PMID 31020423›Full record

ArticleWorld journal of urology2020

Active surveillance outcomes in prostate cancer patients: the use of transperineal template-guided mapping biopsy for patient selection.

Gregory S Merrick, Ava Tennant, Ryan Fiano, Abbey Bennett, Richard Anderson, Robert Galbreath, Wayne M Butler, Edward Adamovich

Abstract read
PubMed Publisher
In one paragraph

Article in World journal of urology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
0.7field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 4 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Gregory S MerrickSchiffler Cancer Center, Wheeling Jesuit University, 1 Medical Park, Wheeling, WV, 26003, USA. gmerrick@urologicresearchinstitute.org.ORCID http://orcid.org/0000-0003-0683-8894
Ava TennantSchiffler Cancer Center, Wheeling Jesuit University, 1 Medical Park, Wheeling, WV, 26003, USA.
Ryan FianoSchiffler Cancer Center, Wheeling Jesuit University, 1 Medical Park, Wheeling, WV, 26003, USA.
Abbey BennettSchiffler Cancer Center, Wheeling Jesuit University, 1 Medical Park, Wheeling, WV, 26003, USA.
Richard AndersonSchiffler Cancer Center, Wheeling Jesuit University, 1 Medical Park, Wheeling, WV, 26003, USA.
Robert GalbreathSchiffler Cancer Center, Wheeling Jesuit University, 1 Medical Park, Wheeling, WV, 26003, USA.
Wayne M ButlerSchiffler Cancer Center, Wheeling Jesuit University, 1 Medical Park, Wheeling, WV, 26003, USA.
Edward AdamovichDepartment Of Pathology, Wheeling Hospital, Wheeling, WV, 26003, USA.
Wheeling Jesuit University · USWheeling Hospital · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo evaluate active surveillance (AS) outcomes including overall survival (OS), freedom from distant metastases (FDM), freedom from therapeutic intervention (FTI), and quality of life (QOL) outcomes in prostate cancer patients using transperineal template-guided mapping biopsy (TTMB) for patient selection.

methodsFrom April 2005-January 2016, 226 consecutive, prospectively evaluated prostate cancer patients underwent TTMB for either low-grade prostate cancer or persistently elevated prostate-specific antigen (PSA) and/or the presence of ASAP. Evaluated outcomes included OS, FDM, FTI and QOL including urinary, bowel, sexual function and depression. Repeat biopsy was based on PSA kinetics and/or abnormal digital rectal examination.

resultsOf the 226 patients, 212 (93.8%) were Gleason 3 + 3 and 14 (6.2%) were Gleason 3 + 4. The median follow-up was 5.0 years (range 0.8-13.0 years). The mean prostate volume was 61.3 cm

conclusionWithin the confines of the follow-up of this study, the use of TTMB for patient selection identifies a cohort of patients unlikely to develop biochemical or clinical progression and maintain a favorable quality of life.

Indexed as

Patient SelectionQuality of LifeAgedAged, 80 and overFollow-Up StudiesHumansImage-Guided BiopsyMaleMiddle AgedProspective StudiesProstateProstatic NeoplasmsWatchful WaitingActive surveillancePatient selectionProstate cancerQOLTransperineal template-guided mapping biopsy

Identifiers

PMID31020423
OpenAlexW2940710243

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.